膜联蛋白A家族成员在乳腺癌中作用机制的研究进展

doi:10.16352/j.issn.1001-6325.2024.03.0393

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (3): 393-397.doi: 10.16352/j.issn.1001-6325.2024.03.0393

膜联蛋白A家族成员在乳腺癌中作用机制的研究进展

南璐¹, 郭梦杰¹, 高雅楠¹, 贾红燕^2*

1.山西医科大学第一临床医学院,山西太原 030001;
2.山西医科大学第一医院乳腺科,山西太原 030001

收稿日期:2023-10-17 修回日期:2023-12-27 出版日期:2024-03-05 发布日期:2024-02-22
通讯作者: ^*:swallow_jhy@163.com
基金资助:
山西省留学人员科技活动择优资助项目(20200036);山西省自然科学基金(201901D111347)

Research progress on the mechanism of annexin A family members in breast cancer

NAN Lu¹, GUO Menjie¹, GAO Yanan¹, JIA Hongyan^2*

1. The First Clinical College of Medicine, Shanxi Medical University, Taiyuan 030001;
2. Department of Breast, the First Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2023-10-17 Revised:2023-12-27 Online:2024-03-05 Published:2024-02-22
Contact: ^*:swallow_jhy@163.com

摘要/Abstract

摘要： 膜联蛋白(ANX)家族广泛存在于细胞膜、细胞质或细胞外基质中。作为肿瘤的关键调控分子,膜联蛋白A(ANX A)家族可以通过影响细胞膜和细胞骨架的形成及参与信号通路,促进或抑制乳腺癌细胞的侵袭与转移。在细胞凋亡方面,ANX A家族通过参与促凋亡蛋白质和细胞周期独立激酶(CDKs)及相关通路的调节,在乳腺癌细胞凋亡中发挥作用。此外,ANX A家族还可以促进大量药物的治疗耐药。例如,ANX A1通过诱导上皮细胞-间质转化增强三阴性乳腺癌耐药,ANX A4通过形成ANX A4-Fhit复合物产生耐药性,含有ANX A6的外泌体的分泌以YAP1依赖的方式促进乳腺癌细胞的紫杉醇耐药。ANX A家族可能成为乳腺癌治疗的新靶点。

关键词: 膜联蛋白A家族, 乳腺癌, 肿瘤发生

Abstract: The annexins(ANX) family is widely present in the cell membrane, cytoplasm or extracellular matrix. As key tumor regulatory molecules, annexins A (ANX A) family can promote or inhibit invasion and metastasis of breast cancer cells by influencing cell membrane and cytoskeleton formation and participating in signaling pathways. ANX A family also plays a role in the apoptosis of breast cancer cells by regulation of pro-apoptotic proteins and cell cycle independent kinases (CDKs) and related pathways. In addition, ANX A family can also promote therapeutic resistance to a large number of drugs. For instance,ANX A1 enhances triple-negative breast cancer resistance by inducing epithelial-mesenchymal transformation. ANX A4 induces resistance by forming ANX A4-Fhit complexes and secretion of exosomes containing ANX A6 promotes paclitaxel resistance in breast cancer cells in a YAP1-dependent manner. So ANX A family may be a new target for breast cancer treatment.

Key words: annexins A family, breast cancer, tumorigenesis

中图分类号:

南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.

NAN Lu, GUO Menjie, GAO Yanan, JIA Hongyan. Research progress on the mechanism of annexin A family members in breast cancer[J]. Basic & Clinical Medicine, 2024, 44(3): 393-397.

参考文献 25

[1]	Li N, Xi Y, Du H, et al. Annexin A4 is dispensable for hair cell development and function[J]. Front Cell Dev Biol, 2021, 9: 680155. doi:10.3389/fcell.2021.680155.
[2]	Hu Z, Li L, Zhu B, et al. Annexin A5 is essential for PKCθtranslocation during T-cell activation[J]. J Biol Chem, 2020, 295: 14214-14221.
[3]	Yu ZZ, Liu YY, Zhu W, et al. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers[J].J Immunother Cancer,2023,11:e006345. doi:10.1136/jitc-2022-006345.
[4]	Głowacka A, Bieganowski P, Jurewicz E, et al. Regula-tion of S100A10 gene expression[J]. Biomolecules,2021,11:974.doi:10.3390/biom11070974.
[5]	Liu J, Wang H, Zheng M, et al. p53 and ANXA4/NF-κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma[J].Int J Mol Med, 2020,46:2102-2114.
[6]	Scala MC, Di Micco S, Lanzillotta D, et al. Overcome chemoresistance: biophysical and structural analysis of synthetic Fhit-derived peptides[J]. Front Mol Biosci, 2021,8:715263. doi:10.3389/fmolb.2021.715263.
[7]	Guo Z, Guo A, Zhou C. Breast cancer stem cell-derived ANXA6-containing exosomes sustain paclitaxel resistance and cancer aggressiveness in breast cancer[J]. Front Cell Dev Biol, 2021, 9: 718721. doi:10.3389/fcell.2021.718721.
[8]	Song L, Li H, Ma RR, et al. E2F1-initiated transcription of PRSS22 promotes breast cancer metastasis by cleaving ANXA1 and activating FPR2/ERK signaling pathway[J]. Cell Death Dis, 2022, 13: 982. doi:10.1038/s41419-022-05414-3.
[9]	Tang L, Chen Y, Chen H, et al. DCST1-AS1 promotes TGF-β-induced epithelial-mesenchymal transition and enhances chemoresistance in triple-negative breast cancer Cells via ANXA1[J]. Front Oncol, 2020, 10: 280. doi:10.3389/fonc.2020.00280.
[10]	Long Y, Chong T, Lyu X, et al. FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer[J].J Exp Clin Cancer Res,2022,41:301.doi:10.1186/s13046-022-02504-0.
[11]	Fan Y, Si W, Ji W, et al. Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells[J]. Breast Cancer Res, 2019, 21: 66. doi:10.1186/s13058-019-1147-7.
[12]	Strand E, Hollås H, Sakya SA, et al. Annexin A2 binds the internal ribosomal entry site of c-myc mRNA and regulates its translation[J]. RNA Biol, 2021,18: 337-354.
[13]	Du R, Liu B, Zhou L, et al. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer[J]. Cell Death Dis,2018, 9: 126. doi:10.1038/s41419-017-0143-z.
[14]	Kim JY, Jung EJ, Park HJ, et al. Tumor-suppressing effect of silencing of annexin A3 expression in breast cancer[J]. Clin Breast Cancer, 2018, 18: e713-e719.
[15]	Kim JY, Jung EJ, Kim JM, et al. miR-221 and miR-222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3[J].Exp Ther Med,2023,25:127. doi:10.3892/etm.2023.11826.
[16]	Li L, Zhang R, Liu Y, et al. ANXA4 activates JAK-STAT3 signaling by interacting with ANXA1 in basal-Like breast cancer[J].DNA Cell Biol, 2020, 39: 1649-1656.
[17]	Hein T, Krammer PH, Weyd H. Molecular analysis of Annexin expression in cancer[J]. BMC cancer, 2022, 22: 994. doi:10.1186/s12885-022-10075-8.
[18]	Kang TH, Park JH, Yang A, et al. Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment[J].Nat Commun,2020,11:1137. doi:10.1038/s41467-020-14821-z.
[19]	Hoque M, Elmaghrabi YA, Köse M, et al. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells[J]. FEBS J, 2020, 287: 2961-2978.
[20]	Sakwe AM, Koumangoye R, Guillory B, et al. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions[J]. Exp Cell Res, 2011, 317: 823-837.
[21]	Li T, Tao Z, Zhu Y, et al. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer[J]. Cell Death Dis, 2021, 12: 684.doi:10.1038/s41419-021-03963-7.
[22]	Williams SD, Smith TM, Stewart LV, et al. Hypoxia-inducible expression of annexin A6 enhances the resistance of triple-negative breast cancer cells to EGFR and AR antagonists[J]. Cells, 2022, 11: 3007.doi:10.3390/cells11193007.
[23]	Rossetti S, Sacchi N. 3D mammary epithelial cell models: a goldmine of DCIS biomarkers and morphogene-tic mechanisms[J]. Cancers, 2019, 11: 130. doi:10.3390/cancers11020130.
[24]	田焕娜,吴雪艳,王小杰.敲低膜联蛋白A7对乳腺癌MCF-7细胞凋亡的影响[J]. 承德医学院学报, 2015: 193-195.
[25]	Wang Z, Zhou X, Deng X, et al. miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer[J]. Front Oncol, 2023, 13: 1166666. doi:10.3389/fonc.2023.1166666.

膜联蛋白A家族成员在乳腺癌中作用机制的研究进展

Research progress on the mechanism of annexin A family members in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[2]	夏雨佳, 杨振丽, 代娣, 刘玉琴. 乳腺癌类器官的培养及鉴定[J]. 基础医学与临床, 2024, 44(9): 1223-1228.
[3]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[4]	依合里曼·买买提, 曹燕珍, 王翠翠, 岳娜, 梁莉萍. PIK3CA突变与乳腺癌临床病理特征及预后的相关性[J]. 基础医学与临床, 2024, 44(3): 303-307.
[5]	李江丽, 孙静, 唐一君, 郭君兰, 陈博, 郭胜男. Circ-DDX5靶向miR-3940抑制人乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2024, 44(1): 1-7.
[6]	陈宁, 彭甜影, 张伟苗, 高亚诺, 李轩, 闫彩珍, 李军霞. 雷公藤甲素与阿霉素联用对人乳腺癌细胞系 MCF-7 的协同促凋亡作用[J]. 基础医学与临床, 2023, 43(8): 1186-1192.
[7]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[8]	唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.
[9]	高欣, 于永波, 王海存, 姜兴明, 王志东. 环状RNA核受体相互作用蛋白1对肿瘤发生发展的调控机制研究进展[J]. 基础医学与临床, 2023, 43(5): 827-832.
[10]	杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.
[11]	王群, 李鑫, 马俊, 李婉明. 核酸适配体W3介导靶向乳腺癌的量子点成像[J]. 基础医学与临床, 2023, 43(1): 76-82.
[12]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.
[13]	王子辕, 段昭君, 罗云萍. 小鼠乳腺癌肺特异性转移细胞亚系的建立和验证[J]. 基础医学与临床, 2022, 42(7): 1083-1091.
[14]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[15]	康有力, 赵丹, 杜文静, 李莉. SIRT5通过调控ALDH5A1的琥珀酰化促进人乳腺癌细胞的增殖[J]. 基础医学与临床, 2022, 42(7): 1099-1107.